Oncotarget

Research Papers:

Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma

Norihiko Tokuzen, Koh-ichi Nakashiro _, Hiroshi Tanaka, Kazuki Iwamoto and Hiroyuki Hamakawa

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:2343-2353. https://doi.org/10.18632/oncotarget.6148

Metrics: PDF 899 views  |   HTML 1126 views  |   ?  


Abstract

Norihiko Tokuzen1, Koh-ichi Nakashiro1, Hiroshi Tanaka1, Kazuki Iwamoto1 and Hiroyuki Hamakawa1

1 Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan

Correspondence to:

Koh-ichi Nakashiro, email:

Keywords: cell division cycle associated 5 (CDCA5), oral squamous cell carcinoma (OSCC), cell cycle, prognosis, molecular targeted therapy

Received: July 02, 2015 Accepted: September 30, 2015 Published: October 19, 2015

Abstract

Molecularly targeted drugs are used in the treatment of a variety of malignant tumors, but this approach to developing novel therapies for oral squamous cell carcinoma (OSCC) has lagged behind the progress seen for other cancers. We have attempted to find appropriate molecular targets for OSCC and identified cell division cycle associated 5 (CDCA5) as a cancer-related gene which was overexpressed in all the human OSCC cells tested by microarray analysis. In this study, we investigated the expression and function of CDCA5 in OSCC. First, we confirmed that CDCA5 was overexpressed in 4 human OSCC cell lines by quantitative RT-PCR and Western blotting. We then tested the effect of synthetic small interfering RNAs specific for CDCA5 on the growth and invasion of human OSCC cells. Knockdown of CDCA5 markedly inhibited the growth of OSCC cells in vitro and in vivo. We also examined the expression of CDCA5 protein in 80 cases of OSCC immunohistochemically and found a significant association between CDCA5 expression levels and overall survival. These results suggest that CDCA5 functions as a critical gene supporting OSCC progression and that targeting CDCA5 may be a useful therapeutic strategy for OSCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6148